23and Me Holding Co. ME
We take great care to ensure that the data presented and summarized in this overview for 23andMe Holding Co. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ME
View all-
New View Capital Partners I, LLC Burlingame, CA19.5MShares$66.7 Million18.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.6MShares$53.4 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY10.2MShares$35.1 Million0.4% of portfolio
-
Sapphire Ventures, L.L.C. Austin, TX5.29MShares$18.2 Million1.93% of portfolio
-
Black Rock Inc. New York, NY4.66MShares$16 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.25MShares$14.6 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.09MShares$10.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.75MShares$9.42 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X02.32MShares$7.94 Million0.06% of portfolio
-
Wittenberg Investment Management, Inc. Carlisle, MA2.31MShares$7.94 Million0.36% of portfolio
Latest Institutional Activity in ME
Top Purchases
Top Sells
About ME
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Insider Transactions at ME
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 26
2024
|
Roelof Botha Director |
BUY
Grant, award, or other acquisition
|
Indirect |
179,586
+27.08%
|
$0
$0.33 P/Share
|
|
Aug 26
2024
|
Roelof Botha Director |
BUY
Grant, award, or other acquisition
|
Direct |
658,485
+50.0%
|
-
|
|
Aug 26
2024
|
Patrick S Chung Director |
BUY
Grant, award, or other acquisition
|
Direct |
860,520
+27.75%
|
$0
$0.17 P/Share
|
|
Aug 26
2024
|
Neal Mohan Director |
BUY
Grant, award, or other acquisition
|
Direct |
658,485
+42.14%
|
-
|
|
Aug 26
2024
|
Rice Valerie Md Montgomery Director |
BUY
Grant, award, or other acquisition
|
Direct |
853,037
+26.63%
|
$0
$0.17 P/Share
|
|
Aug 26
2024
|
Richard H Scheller Director |
BUY
Grant, award, or other acquisition
|
Direct |
658,485
+42.36%
|
-
|
|
Aug 26
2024
|
Sandra R Md Hernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
808,140
+24.76%
|
$0
$0.17 P/Share
|
|
Aug 26
2024
|
Peter J. Taylor Director |
BUY
Grant, award, or other acquisition
|
Direct |
658,485
+40.16%
|
-
|
|
Aug 20
2024
|
Joseph Anthony Selsavage Chief Financial & Actng Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
110,388
-4.89%
|
$0
$0.36 P/Share
|
|
Aug 20
2024
|
William G Richards Head of Therapeutics Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
57,365
-9.1%
|
$0
$0.36 P/Share
|
|
Jun 30
2024
|
Sandra R Md Hernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,515
+12.71%
|
-
|
|
Jun 30
2024
|
Rice Valerie Md Montgomery Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,337
+4.14%
|
-
|
|
Jun 30
2024
|
Peter J. Taylor Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,515
+15.13%
|
-
|
|
May 21
2024
|
Joseph Anthony Selsavage Chief Financial & Actng Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+30.69%
|
-
|
|
May 20
2024
|
William G Richards Head of Therapeutics Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
16,106
-2.49%
|
$0
$0.55 P/Share
|
|
May 20
2024
|
Joseph Anthony Selsavage Chief Financial & Actng Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
36,913
-2.85%
|
$0
$0.55 P/Share
|
|
May 20
2024
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,282
-2.82%
|
$0
$0.55 P/Share
|
|
May 02
2024
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
38,551
-2.99%
|
$0
$0.49 P/Share
|
|
May 02
2024
|
Kathy L Hibbs Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,551
+2.9%
|
$0
$0.42 P/Share
|
|
Apr 18
2024
|
Kathy L Hibbs Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
38,548
-2.99%
|
$0
$0.47 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 6.47M shares |
|---|---|
| Exercise of conversion of derivative security | 463K shares |
| Payment of exercise price or tax liability | 357K shares |
|---|---|
| Open market or private sale | 463K shares |